MIM
EWTX icon

MetLife Investment Management’s Edgewise Therapeutics EWTX Stock Holding History

MetLife Investment Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
41,804
+3,720
+10% +$128K 0.01% 1246
2026
Q1 		$1.2M Sell
38,084
-207
-0.5% -$5.97K 0.01% 1316
2025
Q4 		$950K Sell
38,291
-5,592
-13% -$112K ﹤0.01% 1455
2025
Q3 		$712K Hold
43,883
– – ﹤0.01% 1642
2025
Q2 		$575K Hold
43,883
– – ﹤0.01% 1607
2025
Q1 		$965K Sell
43,883
-729
-2% -$19.1K 0.01% 1387
2024
Q4 		$1.19M Buy
44,612
+2,341
+6% +$74.5K 0.01% 1323
2024
Q3 		$1.13M Hold
42,271
– – 0.01% 1327
2024
Q2 		$761K Buy
42,271
+12,336
+41% +$215K ﹤0.01% 1500
2024
Q1 		$546K Buy
29,935
+6,580
+28% +$105K ﹤0.01% 1626
2023
Q4 		$256K Hold
23,355
– – ﹤0.01% 2094
2023
Q3 		$134K Hold
23,355
– – ﹤0.01% 2430
2023
Q2 		$181K Hold
23,355
– – ﹤0.01% 2340
2023
Q1 		$156K Hold
23,355
– – ﹤0.01% 2363
2022
Q4 		$209K Hold
23,355
– – ﹤0.01% 2223
2022
Q3 		$230K Hold
23,355
– – ﹤0.01% 2202
2022
Q2 		$186K Hold
23,355
– – ﹤0.01% 2376
2022
Q1 		$227K Buy
23,355
+8,328
+55% +$107K ﹤0.01% 2281
2021
Q4 		$230K Buy
+15,027
New +$270K ﹤0.01% 1968

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's EWTX Position: Q2 2026 in Review

MetLife Investment Management increased its Edgewise Therapeutics (EWTX) stake by 9.8% in Q2 2026, buying an estimated $128K and bringing the position to 41,804 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #1246.

MetLife Investment Management first reported a position in EWTX in Q4 2021 and has held it in 19 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • MetLife Investment Management held 41,804 shares of Edgewise Therapeutics worth $1.7M as of Q2 2026.
  • MetLife Investment Management bought 3,720 Edgewise Therapeutics shares in Q2 2026, an estimated $128K.
  • Edgewise Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1246 holding.
  • MetLife Investment Management first reported a position in Edgewise Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.